MaaT Pharma Advances PHOENIX After Negative EMA Opinion
LYON, France — September 18, 2026 MaaT Pharma announced that the Committee for Medicinal Products for Human Use (CHMP)...
MaaT Pharma
Advertisement
MaaT Pharma to Seek EMA Re-Examination for Xervyteg After CHMP Rejection
LYON, France, June 26, 2026 MaaT Pharma announced plans to request a re-examination of the European Medicines Agency (EMA)...
MaaT Pharma Receives Negative CHMP Trend for MaaT013 in aGvHD
Lyon, France, May 20, 2026 MaaT Pharma announced that the Committee for Medicinal Products for Human Use (CHMP) of...
MaaT Pharma CHRONOS Data Reveals Poor aGvHD Survival
LYON, France, April 1, 2026 MaaT Pharma has announced the publication of CHRONOS study data in the peer-reviewed Bone...
MaaT Pharma Advances Phase 2 Trial in ICI-Resistant NSCLC
Lyon, France, January 20, 2026 — MaaT Pharma, a late-stage clinical biotechnology company developing microbiome-driven immunotherapies, announced that the...
Advertisement
